Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia.

Bharati ShriyanParsshava MehtaAnand PatilShraddha JadhavSharath KumarApeksha S PuriRavina GovalkarManjunath Nookala KrishnamurthySachin PunatarAnant GokarnNavin KhattryVikram Gota

Published in: European journal of clinical pharmacology (2022)

Our study conclusively proves that genetic polymorphisms in the CYP3A4 and ABC family of transporters do not have any role in the personalized dosing of imatinib in CML.

Keyphrases

chronic myeloid leukemia
bone marrow
dendritic cells
acute myeloid leukemia
molecular docking